President Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugs
This image was generated by AI and may not depict real events.
The Trump administration signed an executive order to accelerate FDA reviews for psychedelic therapies to treat mental health conditions such as PTSD and depression. The order aims to expedite the review of investigational therapies, particularly for US veterans.
The Trump administration issued an executive order to accelerate research and regulatory review of psychedelic therapies for mental health conditions. Signed in the Oval Office, the order directs the FDA to expedite its review of certain investigational therapies, particularly those already in advanced stages of clinical development, with an initial focus on addressing unmet needs among US veterans. The policy highlights psychedelic compounds, including ibogaine, which has been studied for its potential role in treating PTSD and substance use disorders. The administration also plans to explore pathways for incorporating such treatments under the Right to Try Act. FDA Commissioner Martin Makary suggested the initiative could significantly compress regulatory timelines for qualifying therapies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.